You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Ondansetron (Zofran) Warning Strengthened

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000410355.34028.8a
Drug Watch
Abstract

* The antiemetic ondansetron (Zofran) has undergone a label revision to emphasize the risk of cardiac arrhythmias such as QT-interval prolongation and torsade de pointes.

* Patients with congenital long QT syndrome shouldn't receive ondansetron.

* Cardiac monitoring should be conducted in patients taking ondansetron who have electrolyte imbalances, congestive heart failure, bradyarrythmias, or a history of taking other drugs that prolong the QT interval.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.